Beijing Tiantan Biological Products Corp Ltd
SSE:600161

Watchlist Manager
Beijing Tiantan Biological Products Corp Ltd Logo
Beijing Tiantan Biological Products Corp Ltd
SSE:600161
Watchlist
Price: 20.52 CNY -1.2% Market Closed
Market Cap: 40.6B CNY
Have any thoughts about
Beijing Tiantan Biological Products Corp Ltd?
Write Note

Beijing Tiantan Biological Products Corp Ltd
Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Beijing Tiantan Biological Products Corp Ltd
Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
Beijing Tiantan Biological Products Corp Ltd
SSE:600161
Minority Interest
ÂĄ3.1B
CAGR 3-Years
13%
CAGR 5-Years
21%
CAGR 10-Years
28%
Beigene Ltd
HKEX:6160
Minority Interest
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Minority Interest
ÂĄ183.1m
CAGR 3-Years
90%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Minority Interest
ÂĄ137.1m
CAGR 3-Years
N/A
CAGR 5-Years
85%
CAGR 10-Years
N/A
No Stocks Found

Beijing Tiantan Biological Products Corp Ltd
Glance View

Market Cap
40.6B CNY
Industry
Biotechnology

In the bustling heart of China's biotech industry, Beijing Tiantan Biological Products Corp Ltd emerges as a key player in the crucial field of vaccine and blood product innovations. Rooted in the expansive landscape of pharmaceutical development, the company sets its focus on producing essential vaccines—including those for hepatitis B—and blood-derived products such as albumin, immunoglobulin, and coagulation factor. These products play pivotal roles in preventative healthcare and in treating various diseases. Tiantan Bio operates with a robust integration of research and manufacturing expertise, underpinned by a deep commitment to public health advancement. The company continuously seeks to expand its product offerings, refining processes through relentless research and development to meet the demands of both domestic and international markets. Earnings for Tiantan Biological flow primarily from the successful commercialization of its vaccines and blood products. The company establishes strategic partnerships with research institutions and leverages government healthcare policies that favor domestic vaccine consumption to bolster its market position. Tiantan Bio also invests significantly in infrastructure to upscale its production capabilities, responding to the growing demand for its products. Their business model capitalizes on the symbiotic relationship between research innovation and market needs, ensuring a steady stream of revenue through both public procurement and private healthcare partnerships. This strategic orientation not only showcases its influence in the biotech sphere but also reflects its adaptability and foresight in navigating the dynamic landscape of global healthcare challenges.

Intrinsic Value
25.18 CNY
Undervaluation 19%
Intrinsic Value
Price

See Also

What is Beijing Tiantan Biological Products Corp Ltd's Minority Interest?
Minority Interest
3.1B CNY

Based on the financial report for Sep 30, 2024, Beijing Tiantan Biological Products Corp Ltd's Minority Interest amounts to 3.1B CNY.

What is Beijing Tiantan Biological Products Corp Ltd's Minority Interest growth rate?
Minority Interest CAGR 10Y
28%

Over the last year, the Minority Interest growth was 7%. The average annual Minority Interest growth rates for Beijing Tiantan Biological Products Corp Ltd have been 13% over the past three years , 21% over the past five years , and 28% over the past ten years .

Back to Top